BAY-1816032 is primarily researched for its potential therapeutic applications in the field of oncology. It is being investigated as a targeted therapy for certain types of cancers, particularly those driven by BRCA gene mutations. The compound is a selective inhibitor of the PARP1 enzyme, which plays a key role in DNA repair. By inhibiting PARP1, BAY-1816032 prevents cancer cells from repairing DNA damage, leading to cell death in tumors with impaired DNA repair mechanisms. Preclinical studies suggest its efficacy in suppressing tumor progression in specific cancer models, making it a promising candidate for further clinical development. Ongoing research aims to evaluate its safety, efficacy, and potential use in combination with other cancer therapies, such as chemotherapy or radiation, to enhance treatment outcomes.